Core Viewpoint - Huajian Medical (01931) reported a revenue of 1.27 billion and a profit attributable to shareholders of 39.12 million for the six months ending June 30, 2025, with an adjusted profit of 35.63 million and earnings per share of 2.41 cents [1] Group 1: Financial Performance - The company achieved a revenue of 1.27 billion [1] - Profit attributable to shareholders was 39.12 million [1] - Adjusted profit stood at 35.63 million [1] - Earnings per share were reported at 2.41 cents [1] Group 2: Strategic Outlook - The company aims to consolidate its core IVD business while exploring the strategic value of robotics and cutting-edge technologies [1] - The focus is on leveraging insights into technological innovation and market demand within the medical industry [1] - The company plans to utilize capital markets to strengthen its leading position in China's IVD industry and adopt proactive development strategies [1]